Davercin
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530487

CAS#: 55224-05-0

Description: Davercin, also known as Erythromycin Cyclocarbonate, is a bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. It inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Note: This product is supplied as ethanol solution (100mg/mL)


Chemical Structure

img
Davercin
CAS# 55224-05-0

Theoretical Analysis

MedKoo Cat#: 530487
Name: Davercin
CAS#: 55224-05-0
Chemical Formula: C38H65NO14
Exact Mass: 759.44
Molecular Weight: 759.930
Elemental Analysis: C, 60.06; H, 8.62; N, 1.84; O, 29.47

Price and Availability

Size Price Availability Quantity
25mg USD 150 Ready to ship
50mg USD 250 Ready to ship
100mg USD 450 Ready to ship
200mg USD 750 Ready to ship
1g USD 2450 Ready to ship
2g USD 3650 Ready to ship
Bulk inquiry

Synonym: Erythromycin A; Erythromycin A 11,12-carbonate; Erythromycin A cyclic carbonate; Davercin.

IUPAC/Chemical Name: (3aR,4R,7R,8S,9S,10R,11R,13R,15R,15aR)-10-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-ethyl-11-hydroxy-8-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3a,7,9,11,13,15-hexamethyldecahydro-6H-[1,3]dioxolo[4,5-c][1]oxacyclotetradecine-2,6,14(7H)-trione

InChi Key: NKLGIWNNVDPGCA-ZDYKNUMJSA-N

InChi Code: InChI=1S/C38H65NO14/c1-14-25-38(10)32(52-35(44)53-38)20(4)27(40)18(2)16-36(8,45)31(51-34-28(41)24(39(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-37(9,46-13)30(42)23(7)48-26/h18-26,28-32,34,41-42,45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30+,31-,32-,34+,36-,37-,38-/m1/s1

SMILES Code: CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@H]4OC(=O)O[C@]14C

Appearance: Colorless solution (in ethanol, 100mg/mL)

Purity: >95% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target: Davercin (Erythromycin Cyclocarbonate), a derivative of Erythromycin, is an active against Gram-positive and some Gram-negative microorganisms.
In vitro activity: TBD
In vivo activity: TBD

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 55.0 72.38
Ethanol 100.0 131.59

Preparing Stock Solutions

The following data is based on the product molecular weight 759.93 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: TBD
In vitro protocol: TBD
In vivo protocol: TBD

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Zhang W, Qiu L, Gong A, Yuan X. Isolation and characterization of a high-efficiency erythromycin A-degrading Ochrobactrum sp. strain. Mar Pollut Bull. 2017 Jan 30;114(2):896-902. doi: 10.1016/j.marpolbul.2016.10.076. PubMed PMID: 27863881.

2: Pierattini EC, Francini A, Raffaelli A, Sebastiani L. Morpho-physiological response of Populus alba to erythromycin: A timeline of the health status of the plant. Sci Total Environ. 2016 Nov 1;569-570:540-7. doi: 10.1016/j.scitotenv.2016.06.152. PubMed PMID: 27366984.

3: Chen D, Wu J, Liu W. [Biosynthesis-based production improvement and structure modification of erythromycin A]. Sheng Wu Gong Cheng Xue Bao. 2015 Jun;31(6):939-54. Review. Chinese. PubMed PMID: 26672369.

4: Jiang M, Fang L, Pfeifer BA. Improved heterologous erythromycin A production through expression plasmid re-design. Biotechnol Prog. 2013 Jul-Aug;29(4):862-9. doi: 10.1002/btpr.1759. PubMed PMID: 23804312.

5: Magee TV, Han S, McCurdy SP, Nguyen TT, Granskog K, Marr ES, Maguire BA, Huband MD, Chen JM, Subashi TA, Shanmugasundaram V. Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates. Bioorg Med Chem Lett. 2013 Mar 15;23(6):1727-31. doi: 10.1016/j.bmcl.2013.01.067. PubMed PMID: 23414806.

6: Jiang M, Zhang H, Pfeifer BA. The logic, experimental steps, and potential of heterologous natural product biosynthesis featuring the complex antibiotic erythromycin A produced through E. coli. J Vis Exp. 2013 Jan 13;(71):e4346. doi: 10.3791/4346. PubMed PMID: 23354010; PubMed Central PMCID: PMC3582574.

7: Romøren M, Lindbæk M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway. Br J Clin Pharmacol. 2012 Dec;74(6):1053-62. doi: 10.1111/j.1365-2125.2012.04286.x. PubMed PMID: 22463376; PubMed Central PMCID: PMC3522819.

8: Brüning J, Trepte TK, Bats JW, Schmidt MU. Erythromycin A dimethyl sulfoxide disolvate 1.43-hydrate. Acta Crystallogr Sect E Struct Rep Online. 2012 Mar 1;68(Pt 3):o700-1. doi: 10.1107/S1600536812005223. PubMed PMID: 22412590; PubMed Central PMCID: PMC3295479.

9: Zhang H, Skalina K, Jiang M, Pfeifer BA. Improved E. coli erythromycin A production through the application of metabolic and bioprocess engineering. Biotechnol Prog. 2012 Jan-Feb;28(1):292-6. doi: 10.1002/btpr.702. PubMed PMID: 21905273.

10: Wu J, Zhang Q, Deng W, Qian J, Zhang S, Liu W. Toward improvement of erythromycin A production in an industrial Saccharopolyspora erythraea strain via facilitation of genetic manipulation with an artificial attB site for specific recombination. Appl Environ Microbiol. 2011 Nov;77(21):7508-16. doi: 10.1128/AEM.06034-11. PubMed PMID: 21841022; PubMed Central PMCID: PMC3209160.

11: Sugawara A, Sueki A, Hirose T, Nagai K, Gouda H, Hirono S, Shima H, Akagawa KS, Omura S, Sunazuka T. Novel 12-membered non-antibiotic macrolides from erythromycin A; EM900 series as novel leads for anti-inflammatory and/or immunomodulatory agents. Bioorg Med Chem Lett. 2011 Jun 1;21(11):3373-6. doi: 10.1016/j.bmcl.2011.04.004. PubMed PMID: 21524580.

12: Ma X, Ma S. Significant breakthroughs in search for anti-infectious agents derived from erythromycin A. Curr Med Chem. 2011;18(13):1993-2015. Review. PubMed PMID: 21517774.

13: Zhang L, Jiao B, Yang X, Liu L, Ma S. Synthesis and antibacterial activity of new 4″-O-carbamates of 11,12-cyclic carbonate erythromycin A 6,9-imino ether. J Antibiot (Tokyo). 2011 Mar;64(3):243-7. doi: 10.1038/ja.2010.166. Erratum in: J Antibiot (Tokyo). 2012 Feb;65(2):115. PubMed PMID: 21245870.

14: Zhang H, Wang Y, Wu J, Skalina K, Pfeifer BA. Complete biosynthesis of erythromycin A and designed analogs using E. coli as a heterologous host. Chem Biol. 2010 Nov 24;17(11):1232-40. doi: 10.1016/j.chembiol.2010.09.013. PubMed PMID: 21095573.

15: Luiz DB, Genena AK, Virmond E, José HJ, Moreira RF, Gebhardt W, Schröder HF. Identification of degradation products of erythromycin A arising from ozone and advanced oxidation process treatment. Water Environ Res. 2010 Sep-Oct;82(9):797-805. PubMed PMID: 20942335.

16: Qi Y, Jiao B, Ma X, Cui W, Ma S. Synthesis and antibacterial activity of novel 4''-O-carbamoyl erythromycin-A derivatives. Arch Pharm (Weinheim). 2010 Aug;343(8):458-64. doi: 10.1002/ardp.200900288. PubMed PMID: 20803622.

17: Shiina I, Katoh T, Nagai S, Hashizume M. Evaluation of the efficiency of the macrolactonization using MNBA in the synthesis of erythromycin A aglycon. Chem Rec. 2009;9(6):305-20. doi: 10.1002/tcr.200900017. Erratum in: Chem Rec. 2010 Apr 26;10(2) doi: 10.1002/tcr.201090004. PubMed PMID: 20041452.

18: Namikawa H, Sunazuka T, Kitamura Y, Suzuki T, Hamasaki Y, Yamazaki S, Omura S, Hatamochi A. Effect of erythromycin A and its new derivative EM201 on type I collagen production by cultured dermal fibroblasts. Arch Dermatol Res. 2010 Jul;302(5):341-8. doi: 10.1007/s00403-009-0977-z. PubMed PMID: 19578864.

19: Zou X, Hang HF, Chu J, Zhuang YP, Zhang SL. Enhancement of erythromycin A production with feeding available nitrogen sources in erythromycin biosynthesis phase. Bioresour Technol. 2009 Jul;100(13):3358-65. doi: 10.1016/j.biortech.2009.01.064. PubMed PMID: 19268575.

20: Pandey D, Haq W, Katti SB. New acylides: synthesis of 3-O-[gamma-(4-oxo-2-aryl-thiazolidin-3-yl)butyryl]erythromycin A derivatives. Beilstein J Org Chem. 2008;4:14. doi: 10.3762/bjoc.4.14. PubMed PMID: 18941486; PubMed Central PMCID: PMC2486485.